View Printer-Friendly PDF

A Drug Development & Outsourcing Profile

Alectos Therapeutics

8999 Nelson Way
Burnaby BC  V5A 4B5
Canada

  • Tel: 604-628-7129
  • Fax: 604-628-0137
  • CEO: Ernest McEachern
  • Mktg:
  • R&D:
  • Licng:
  • Est: Private
  • Rev: $ M
  • Staff:
  • CNS/Neurology
  • Alzheimers
  • Parkinsons

Alectos Therapeutics is a privately held pharmaceutical company dedicated to the discovery and development of novel small-molecule therapeutics for the treatment of human disease. The company's focus centers on preclinical CNS drug development, target validation, hit-to-lead optimization, and IND-enabling studies. The Alectos pipeline includes development of novel disease-modifying agents for treatment of Progressive Supranuclear Palsy, Alzheimer’s disease, Parkinson’s disease, and Niemann-Pick type C disease.

Mfg:    Labs:

0.0037